HBV Mutation Detail Information

> A128V Search Result


Mutation Information
Mutation Site A128V
Mutation Type Amino acid level
Gene/Protein/Region Type S
Genotype/Subtype A;D
Viral Reference JN182318.1; GU456636.1
Immune Escape Y
Literature Information
PubMed PMID 29859062
Disease Chronic hepatitis B
Published Year 2018
Journal BMC infectious diseases
Title Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
Author Colagrossi L,Hermans LE,Salpini R,Di Carlo D,Pas SD,Alvarez M,Ben-Ari Z,Boland G,Bruzzone B,Coppola N,Seguin-Devaux C,Dyda T,Garcia F,Kaiser R,Köse S,Krarup H,Lazarevic I,Lunar MM,Maylin S,Micheli V,Mor O,Paraschiv S,Paraskevis D,Poljak M,Puchhammer-Stöckl E,Simon F,Stanojevic M,Stene-Johansen K,Tihic N,Trimoulet P,Verheyen J,Vince A,Lepej SZ,Weis N,Yalcinkaya T,Boucher CAB,Wensing AMJ,Perno CF,Svicher V,HEPVIR working group of the European Society for translational antiviral research (ESAR).
Evidence These results were confirmed also when the analysis was focused on LAM-treated patients, thus limiting the impact of anti-HBV drugs on the selection of these mutations (sA128V: 4.4%[16/362] vs 0.5%[2/209], P = 0.008; sP120S: 5.5%[20/362] vs 1%[2/209], P = 0.006; sG130N: 0.3%[1/362] vs 1.9%[4/209], P = 0.063).

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation